Delivery Order SPE2DB22D1200-SPE2DB25FN3PG
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Xolair 300 mg/2 ml auto-injector units valued at $1,594.16. This is a firm fixed price delivery order with an ultimate completion date of August 8, 2025, and no set-aside designation was applied. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Xolair 300 mg/2 mL auto-injectors with a ceiling value of $3,188.32. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 21, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a single delivery order issued under AmerisourceBergen's larger indefinite delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $15,941.60 on July 23, 2025, for the supply of Xolair 300 mg/2 ml auto-injector units. This is a firm fixed-price delivery order with an ultimate completion date of August 13, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp will perform this contract from its corporate office location in Conshohocken, Pennsylvania, the company's headquarters. The delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xolair 300 mg/2 ml auto-injector vials with a ceiling value of $1,594.16. This delivery order, issued on June 20, 2025, with an ultimate completion date of July 14, 2025, operates under a firm fixed-price contract structure with no set-aside designation. The product will be delivered to the company's facility in Conshohocken, Pennsylvania. This award represents a continuation of...
- The Defense Logistics Agency awarded a $6,376.64 delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Xolair 300 mg/2 ml auto-injector vials. This firm fixed-price delivery order, with an ultimate completion date of July 11, 2025, represents a non-competitive set-aside award and will be fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract falls under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Xolair 300 mg/2 ml auto-injector vials with a firm fixed price ceiling value of $3,188.32 and an ultimate completion date of August 26, 2025. This non-set-aside, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The contract will be performed at...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 17, 2025, for the supply of Xolair 300 mg/2 mL auto-injector units. This non-set-aside, competitively awarded delivery order carries a ceiling value of $1,594.16 with firm fixed pricing and is scheduled for completion by August 7, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Xolair 300 mg/2 ml auto-injector doses with a ceiling value of $1,594.16 and a firm fixed price arrangement. The contract, which represents a non-set-aside, competitively awarded procurement, is scheduled for ultimate completion by August 26, 2025. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Xolair 300 mg/2 mL auto-injector units with a firm fixed price ceiling value of $1,594.16 and an ultimate completion date of August 26, 2025. This non-set-aside award operates as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at approximately $1 billion through December 2026. The product...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Xolair 300 mg/2 mL auto-injectors with a ceiling value of $1,594.16 and a firm fixed price structure. The order is scheduled for completion by August 11, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. This delivery order is issued under a non-set-aside, competitive procurement process and represents a continuation of the pharmaceutical...
- SPE2DB22D1200Indefinite Delivery Contract
- SPE2DB22D1200-SPE2DB25FN3PGDelivery Order
The Defense Logistics Agency awarded a $3,188.32 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Xolair 300 mg/2 ml auto-injector vials. This is a firm fixed price, competitively awarded contract with an ultimate completion date of August 25, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026, serving as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting the Defense Health Agency and military healthcare systems. The company has demonstrated extensive capability in fulfilling diverse federal pharmaceutical needs through multiple competitively awarded contracts with the DLA, spanning brand-name and generic medications, vaccines, specialty treatments, and medical devices across numerous therapeutic domains. This award reflects the company's ongoing role in the DLA's medical supply chain and its ability to meet federal procurement requirements for specialized pharmaceutical products supporting military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.2k | 8/4/25 |